Looking to know more about the RMSL Stock? Wondering how they have performed and what are their prospects?
The article addresses those concerns and dives deep into understanding the performance of the RMSL Stock. It also provides insights into the stock’s performance as analyzed by various analysts to give a holistic idea about its growth potential.
RemSleep Holdings, Inc. manufactures medical devices serving home care dealers, private sleep labs, product end users, sleep product distributors, physicians, medical groups, hospitals, and medical associations. They put a lot of emphasis on developing revolutionary products that would radically improve the treatment available to obstructive Sleep Apnea patients.
Their focus is on designing and manufacturing devices and products that would enhance the treatment of patients with Sleep Apnea and other respiratory conditions.
They have a dedicated team with extensive knowledge and vast experience of thirty years in CPAP therapy. They aim to understand the challenges, overcome them and provide the best treatment possible to patients suffering from Sleep Apnea.
Their Founder, Russell F. Bird, has a rich business history, especially in the medical field. He founded Medical Gases Australia in 1979. He then started treating patients with CPAP with the help of Dr. Collin Sullivan, often called the “Grandfather of CPAP therapy.”
He then started Medical Industries America in 1985, a $25 million company. He also owned EVO Medical Solutions, which produced respiratory products and devices. He later sold the company.
On the other hand, the CEO, Thomas J. Wood, has multiple patents to his name. He was part of the Muscular Dystrophy Association, where he specialized in Amyotrophic Lateral Sclerosis.
Company Details | REMSleep Holdings Inc. |
Headquarters | Clearwater, Florida, USA |
Year Founded | 2007 |
Founder | Russell Bird |
CEO | Tom Wood |
Industry | Medical Specialties |
Sector | Health Technology |
Number of Employees | <25 |
Market Cap | $24.117 million |
Revenue | $257,240 |
Company website |
Let us analyze the performance statistic and how the RemSleep Stock performed.
The details of the RemSleep statistics, as fetched from Yahoo Finance, are as follows:
Profit Margin | 0.00% |
Operating Margin (ttm) | -357.71% |
Return on Assets (ttm) | -18.39% |
Return on Equity (ttm) | -54.67% |
Revenue (ttm) | 257.24k |
Revenue Per Share (ttm) | 0.00 |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | N/A |
EBITDA | -857.22k |
Net Income Avi to Common (ttm) | -1.23M |
Diluted EPS (Earnings Per Share) (ttm) | -0.0000 |
Quarterly Earnings Growth (yoy) | N/A |
Total Cash (mrq) | 2.16M |
Total Cash Per Share (mrq) | 0 |
Total Debt (mrq) | 473.95k |
Total Debt/Equity (mrq) | 15.16 |
Current Ratio (mrq) | 7.65 |
Book Value Per Share (mrq) | 0.00 |
Operating Cash Flow (ttm) | -2.04M |
Levered Free Cash Flow (ttm) | -2.27M |
Legend: ttm – trailing twelve months, yoy – year over year, mrq – most recent quarter
52-Week Change | -28.42% |
S&P500 52-Week Change | -12.21% |
52 Week High | 0.0430 |
52 Week Low | 0.0090 |
50-Day Moving Average | 0.0171 |
200-Day Moving Average | 0.0171 |
Avg Vol (3 month) | 2.61M |
Avg Vol (10 day) | 2.47M |
Shares Outstanding | 1.46B |
Implied Shares Outstanding | N/A |
Float | 1.41B |
% Held by Insiders | 3.64% |
% Held by Institutions | 0.05% |
Shares Short | N/A |
Short Ratio | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Shares Short (prior month ) | N/A |
3.64% | % of Shares Held by All Insider |
0.05% | % of Shares Held by Institutions |
0.05% | % of Float Held by Institutions |
1 | Number of Institutions Holding Shares |
Holder | Shares | Date Reported | % Out | Value |
North Star Asset Management Inc. | 720,000 | Dec 30, 2022 | 0.05% | 11,879 |
Based on the technical analysis provided by Tradingview analysts,
Let us now look at some important points about RemSleep and the RMSL Stock provided by Simply Wall ST.
REMSleep Holdings Inc. has hardly any revenue, so we use the Price to Book Ratio to analyze the relative value.
The Price to Book ratio is calculated by dividing the share price by the company’s Book Value per share. It indicates how much potential investors have to pay for each dollar of the company’s book value which is Assets minus Liabilities.
The PB Ratio of RMSL is 7.7x
Based on the analysis, it is deduced that RMSL has a good Price to Book Ratio of 7.7x compared to its peers, who have an average of 40.6x
Based on the analysis, it can be seen that RMSL is expensive, with a Price to Book Ratio of 7.7x compared to its US Medical Equipment Industry, which has an average of 2.3x.
Note: Tradingview and Simply Wall ST have concluded that more data is needed from RMSL for meaningful revenue projections and price forecasts.
Based on analysts at Walletinvestor, RMSL has a one-year forecast of $15.34 and a 5-year forecast of $382.63. However, given the current situation, this seems unlikely.
Learn About:
Let’s check the RemSleep Product Line.
Also Read:
No, given the current condition of its business, most analysts have given either a sell-it or a neutral signal. The return has also been below par compared to its competitors and the industry. However, if FDA approves DeltaWave, then the situation may change.
RMSL stock can be bought through any online brokerage service like any other stock.
Yes, their CPAP machine ResPlus, is FDA-approved, and their new device DeltaWave, is pending FDA approval.
Read More:
REMSleep Holdings Inc. is a dynamic medical innovation firm focusing on a specific area of the medical equipment industry in the United States. They have a good value proposition.
However, as evident from their financials, they don’t have a huge market capitalization. They also have a huge debt which is understandable for an R&D-based product company. Still, they need to focus on sales, which ultimately boils down when the company’s survival is questioned.
They have good products, and if they get the FDA approval on their DeltaWave, then it may become a game changer.
Although their stocks have not performed well, the entry of an innovative product such as DeltaWave can completely change the game for RemSleep, and the investors would also get a good return from their RMSL stock.
Disclaimer: All the information presented in the article has been collected independently by BitMoneyAlpha and has not been reviewed or approved by RemSleep. The product information may vary. Please check the company website for the latest information. The statements and opinions expressed in this article belong to the author and do not necessarily represent the views or opinions of any company. The content is for informational purposes only. It is not financial advice. So, before investing, do your due diligence and always invest what you are comfortable losing, as all investments are your responsibility.
Share this post:
Table of Contents Want to know about NIO Hong Kong Stock in detail? Wondering about its performance and what’s in store for NIO in the
Table of Contents Confused about MMAT and MMTLP stock? Want to know what is happening with Meta Materials? The article aims to identify the issues
Table of Contents Confused about KMPH Stock and ZVRA Stock? Still wondering what happened to the KMPH ticker and want to learn more about KemPharm?
